Press Releases

Advanced Search
  • Feb 1, 2008

    Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding its appeal of the Agency's Approvable...

  • Jan 8, 2008

    Cipher Pharmaceuticals Inc. (TSX: DND), an emerging specialty pharmaceutical company, today provided an update on recent developments with its products. CIP-ISOTRETINOIN In June 2007, Cipher...

  • Dec 5, 2007

    Cipher Pharmaceuticals Inc. (TSX: DND) today announced that Dr. Stefan Aigner, M.D., CFA, has been appointed to its Board of Directors. Dr. Aigner has more than 20 years of experience in the...

  • Dec 4, 2007

    Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has appealed the position taken by the U.S. Food and Drug Administration (FDA) in its approvable letter for CIP-TRAMADOL ER, using...

  • Nov 7, 2007

    Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months ended September 30, 2007.Q3 2007 Summary --------------- - Entered into a...